STAT3 and lung carcinoma: Although two HDACis, LBH589 and AR-42, have been shown to reduce STAT3 levels in human lung cancer cells and malignant mast cell disease, respectively [37,38], the effects of SNDX-275 on STAT3 activation and/or expression in MM cells remain unknow.